LY 306740

Drug Profile

LY 306740

Latest Information Update: 01 Aug 2002

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer Nonindustrial source
  • Class Acetamides; Anti-inflammatories; Antiasthmatics
  • Mechanism of Action Neurokinin 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Pain

Most Recent Events

  • 18 Jan 2000 New profile
  • 18 Jan 2000 Preclinical development for Pain in Germany (Unknown route)
  • 18 Jan 2000 Preclinical development for Pain in Portugal (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top